Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ABL Bio Corp.

http://www.ablbio.com

Latest From ABL Bio Corp.

NeuroDerm Parkinson’s Drug Inches Closer To Market With Phase III Win

Mitsubishi Tanabe Pharma paid $1.1bn to acquire the Israeli biotech in 2017 for a drug that analysts forecast to represent a market opportunity worth up to $1.7bn in peak sales.

Clinical Trials Business Strategies

Will The Dark Tunnel For Korean Biopharmas End In 2023?

Scrip wraps up major R&D and corporate developments for Korean biopharmas in 2022 and outlines what lies ahead for them in the new year.

Commercial South Korea

LegoChem’s $1.2bn ADC Platform Deal With Amgen Signals Continued Big Pharma Interest

LegoChem’s hefty out-licensing deal with Amgen seems to further prove global pharma’s keen interest in the Korean ADC leader’s technology, said to be differentiated with safer margins.

Commercial South Korea

The Busiest Dealmakers Of 2022

With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.

Outlook 2023 M & A
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register